{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
PetVivo Holdings, Inc.
PetVivo Holdings Hits New 52-Week High, Surging 61% in Last Year
PetVivo Holdings, Inc. has achieved a 52-week high, reflecting a significant performance increase over the past year, outpacing broader market growth. Despite this milestone, the company faces challenges, including a negative return on equity and a unique financial structure, as it navigates the competitive pharmaceuticals and biotechnology sector.
Is PetVivo Holdings, Inc. overvalued or undervalued?
As of October 5, 2023, PetVivo Holdings, Inc. is considered attractive and undervalued, with a P/E ratio of 12.5 and a P/B ratio of 1.8, both lower than its peers, indicating it is trading at a discount relative to the industry.
Is PetVivo Holdings, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for PetVivo Holdings, Inc. to determine a bullish or bearish outlook.
What does PetVivo Holdings, Inc. do?
PetVivo Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $2 million as of December 2024, with a market cap of $16.49 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of 863.13%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
